2020
Reply from authors: Are we really reducing, refining, and replacing?
Robinson NB, Hameed I, Gaudino M. Reply from authors: Are we really reducing, refining, and replacing? Journal Of Thoracic And Cardiovascular Surgery 2020, 160: e36-e37. PMID: 32414593, DOI: 10.1016/j.jtcvs.2020.03.142.Peer-Reviewed Original ResearchAnimalsCardiac Surgical ProceduresThe translation of surgical animal models to human clinical research: A cross-sectional study
Ruan Y, Robinson NB, Khan FM, Hameed I, Rahouma M, Naik A, Oakley CT, Rong L, Girardi LN, Gaudino M. The translation of surgical animal models to human clinical research: A cross-sectional study. International Journal Of Surgery 2020, 77: 25-29. PMID: 32198098, DOI: 10.1016/j.ijsu.2020.03.023.Peer-Reviewed Original ResearchConceptsSurgical animal modelsAnimal modelsClinical researchAnimal studiesSurgical modelCross-sectional studyBasic science studiesStudy-level analysisRetrospective reviewHuman clinical researchClinical studiesMedian numberGeneral surgeryHuman studiesMaxillofacial surgeryOrthopedic surgerySurgeryPorcine modelPlastic surgerySurgical specialtiesClinical journalsSurgical researchPoor translationSpecialtiesRegression
2019
The current state of animal models in research: A review
Robinson NB, Krieger K, Khan FM, Huffman W, Chang M, Naik A, Yongle R, Hameed I, Krieger K, Girardi LN, Gaudino M. The current state of animal models in research: A review. International Journal Of Surgery 2019, 72: 9-13. PMID: 31627013, DOI: 10.1016/j.ijsu.2019.10.015.Peer-Reviewed Original ResearchCommentary: Do not kill (especially for nothing)
Hameed I, Gaudino M. Commentary: Do not kill (especially for nothing). Journal Of Thoracic And Cardiovascular Surgery 2019, 158: 1557-1558. PMID: 31444068, DOI: 10.1016/j.jtcvs.2019.07.050.Peer-Reviewed Original Research
2018
Efficacy of gefitinib-celecoxib combination therapy in docetaxel-resistant prostate cancer
Lin JZ, Hameed I, Xu Z, Yu Y, Ren ZY, Zhu JG. Efficacy of gefitinib-celecoxib combination therapy in docetaxel-resistant prostate cancer. Oncology Reports 2018, 40: 2242-2250. PMID: 30066906, DOI: 10.3892/or.2018.6595.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBiomarkers, TumorCelecoxibCell ProliferationCyclooxygenase 2 InhibitorsDocetaxelDrug Resistance, NeoplasmGefitinibHumansMaleMiceMice, Inbred BALB CMice, NudeNeoplasm InvasivenessProstatic NeoplasmsQuinazolinesTaxoidsTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsCastration-resistant prostate cancerDocetaxel-resistant castration-resistant prostate cancerEpidermal growth factor receptorCombination therapyCOX-2Prostate cancerKi-67Human castration-resistant prostate cancerCOX-2 protein expression levelsDocetaxel-resistant prostate cancerCombined inhibitionCleaved-caspase-3 protein expressionDocetaxel-resistant prostate cancer cell linesCombination therapy groupDose-escalating mannerProstate cancer cell linesMajor clinical problemABCB1 expression levelsBcl-2COX-2 inhibitionEffect of gefitinibNovel combination therapiesFluorescence-activated cell sorting (FACS) analysisExpression levelsCell lines